PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response

There is a need to develop new, more efficient therapies for head and neck cancer (HNSCC) patients. It is currently unclear whether defects in DNA repair genes play a role in HNSCCs' resistance to therapy. PARP1 inhibitors (PARPi) were found to be “synthetic lethal” in cancers deficient in BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurster, Stephanie, Hennes, Fabian, Parplys, Ann C., Seelbach, Jasna I., Mansour, Wael Y., Zielinski, Alexandra, Petersen, Cordula, Clauditz, Till S., Münscher, Adrian, Friedl, Anna A., Borgmann, Kerstin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891080/
https://www.ncbi.nlm.nih.gov/pubmed/26799421
http://dx.doi.org/10.18632/oncotarget.6947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891080/
https://www.ncbi.nlm.nih.gov/pubmed/26799421
http://dx.doi.org/10.18632/oncotarget.6947

Ejemplares similares